by Lyla El-Fayomi | Mar 12, 2026
Somehow we are already into March, and spring – at least in some places – feels close by. To catch you up, I’ve put together a recap of some of the research that scientists were buzzing about in the field of regenerative medicine from 2025; I cover the good, the bad,...
by Laya Kiani | Feb 12, 2026
In 2025, cell and gene therapy (CGT) showed growing clinical familiarity even as access and reimbursement challenges persisted. Providers and payers increasingly trusted and valued CGTs, supporting the continued expansion of late-stage programs. However, startup...
by Cal Strode | Jan 28, 2026
This year marks the fourth consecutive time I’ve covered the Alliance for Regenerative Medicine’s (ARM) State of the Industry briefing for Signals, and I’ve enjoyed tracking how the cell and gene therapy sector has evolved in real time. In 2023 and 2024, the briefings...
by Stacey Johnson | Jan 9, 2026
It’s that time of year when we look back at what was popular on Signals over the past 12 months, according to views. I am always curious to see what you are reading and perhaps you are as well? As we head into our 14th year of publishing Signals, I’m very aware of all...
by Stacey Johnson | Dec 19, 2025
A recent publication on the marketing of stem cell supplements, in the International Society for Stem Cell Research’s (ISSCR) Stem Cell Reports, sparked my curiosity about these products. While I haven’t been able to find a reliable source indicating how long stem...
by Anis Fahandej-Sadi | Jun 5, 2025
Cancer treatment has advanced dramatically, but a central challenge remains: the newest tools in our arsenal are shockingly expensive. CAR T-cell therapies exemplify this—they’re amazing at fighting blood cancers, but a single treatment costs upwards of...
Comments